Skip to Content
Merck

SML1103

Entecavir

≥98% (HPLC), Nucleic acid synthesis inhibitor, powder

Synonym(s):

2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one, BMS 200475, SQ 34,676

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C12H15N5O3
CAS Number:
142217-69-4
Molecular Weight:
277.28
UNSPSC Code:
51111800
PubChem Substance ID:
329825478
NACRES:
NA.77
MDL number:
MFCD11046562
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Entecavir, ≥98% (HPLC)

SMILES string

O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1

InChI

1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1

InChI key

QDGZDCVAUDNJFG-FXQIFTODSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +25 to +40°, c = 0.2 in H2O

storage condition

desiccated

color

white to beige

solubility

H2O: 0.5 mg/mL, clear (warmed)

storage temp.

−20°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Entecavir is an antiviral guanine analog that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir is used to treat hepatitis B.
Entecavir is an antiviral guanine analog that inhibits reverse transcription, DNA replication and transcription.
Entecavir is used as an effective drug to treat lamivudine-refractory patients with chronic hepatitis B virus (CHB) at a dose of 1 mg daily.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

hcodes

H302,H351

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000341185
0000341185
0000397849
0000283684
0000245721

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wei Wei et al.
Cancer communications (London, England), 38(1), 61-61 (2018-10-12)
The optimal strategy for adjuvant therapy after curative resection for hepatocellular carcinoma (HCC) patients with solitary tumor and microvascular invasion (MVI) is controversial. This trial evaluated the efficacy and safety of adjuvant transcatheter arterial chemoembolization (TACE) after hepatectomy versus hepatectomy
Entecavir therapy for lamivudine?refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, et al.
Hepatology, 48(1), 99-108 (2008)
Yunjian Zeng et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(4), 1414-1419 (2019-10-28)
To investigate the therapeutic effect of 125I seed implantation combined with chemotherapy and antiviral therapy on hepatitis B virus (HBV)-related liver cancer. A total of 126 patients with HBV-related liver cancer were selected and divided into observation group (n=63) and
Hideki Wakasugi et al.
Cancer letters, 434, 91-100 (2018-07-22)
Hepatitis B virus (HBV) infection is a major cause of hepatocellular carcinoma (HCC). Nucleos(t)ide analogue (NA) therapy effectively reduces the incidence of HCC, but it does not completely prevent the disease. Here, we show that dysregulation of microRNAs (miRNAs) is
Tung-Hung Su et al.
Liver international : official journal of the International Association for the Study of the Liver, 36(12), 1755-1764 (2016-09-17)
Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long-term entecavir therapy in reduction of the risk of hepatocellular carcinoma (HCC), cirrhotic events and mortality in a
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service